These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
190 related articles for article (PubMed ID: 9049780)
1. Cell death and the immune response: a lesson from the privileged. Ferguson TA; Griffith TS J Clin Immunol; 1997 Jan; 17(1):1-10. PubMed ID: 9049780 [No Abstract] [Full Text] [Related]
2. The role of FasL-induced apoptosis in immune privilege. Griffith TS; Ferguson TA Immunol Today; 1997 May; 18(5):240-4. PubMed ID: 9153956 [No Abstract] [Full Text] [Related]
3. A vision of cell death: insights into immune privilege. Ferguson TA; Griffith TS Immunol Rev; 1997 Apr; 156():167-84. PubMed ID: 9176707 [TBL] [Abstract][Full Text] [Related]
4. Ocular immunosuppressive microenvironment. Taylor AW Chem Immunol; 1999; 73():72-89. PubMed ID: 10590575 [No Abstract] [Full Text] [Related]
5. CD95-induced apoptosis of lymphocytes in an immune privileged site induces immunological tolerance. Griffith TS; Yu X; Herndon JM; Green DR; Ferguson TA Immunity; 1996 Jul; 5(1):7-16. PubMed ID: 8758890 [TBL] [Abstract][Full Text] [Related]
6. The role of Fas/FasL in immunosuppression induced by human tumors. Whiteside TL; Rabinowich H Cancer Immunol Immunother; 1998 Jun; 46(4):175-84. PubMed ID: 9671140 [No Abstract] [Full Text] [Related]
8. Role of Fas ligand in conferring immune privilege to non-lymphoid cells. Guller S Ann N Y Acad Sci; 1997 Sep; 828():268-72. PubMed ID: 9329847 [No Abstract] [Full Text] [Related]
9. Die and let live: eliminating dangerous lymphocytes. Abbas AK Cell; 1996 Mar; 84(5):655-7. PubMed ID: 8625402 [No Abstract] [Full Text] [Related]
10. Apoptosis and CD95 ligand in immune privileged sites. Bellgrau D; Duke RC Int Rev Immunol; 1999; 18(5-6):547-62. PubMed ID: 10672501 [No Abstract] [Full Text] [Related]
12. Role for NK-cell-associated Fas ligand in cell-mediated cytotoxicity and apoptosis. Eischen CM; Leibson PJ Res Immunol; 1997; 148(3):164-9. PubMed ID: 9255868 [No Abstract] [Full Text] [Related]
13. On the role and significance of Fas (Apo-1/CD95) ligand (FasL) expression in immune privileged tissues and cancer cells using multiple myeloma as a model. Greil R; Egle A; Villunger A Leuk Lymphoma; 1998 Nov; 31(5-6):477-90. PubMed ID: 9922038 [TBL] [Abstract][Full Text] [Related]
14. Soluble Fas and soluble Fas ligand proteins in human milk: possible significance in the development of immunological tolerance. Srivastava MD; Srivastava BI Scand J Immunol; 1999 Jan; 49(1):51-4. PubMed ID: 10023857 [TBL] [Abstract][Full Text] [Related]
15. Cell death and immune privilege. Ferguson TA; Green DR; Griffith TS Int Rev Immunol; 2002; 21(2-3):153-72. PubMed ID: 12424841 [TBL] [Abstract][Full Text] [Related]
16. Functional Fas and Fas-ligand activities in activated T cells of kidney transplant recipients. Nakajima H; Oka T Transplant Proc; 1997 Sep; 29(6):2533-4. PubMed ID: 9290729 [No Abstract] [Full Text] [Related]
17. Fas-ligand: privilege and peril. Green DR; Ware CF Proc Natl Acad Sci U S A; 1997 Jun; 94(12):5986-90. PubMed ID: 9177153 [No Abstract] [Full Text] [Related]
19. The role of Fas ligand in immune privilege. Green DR; Ferguson TA Nat Rev Mol Cell Biol; 2001 Dec; 2(12):917-24. PubMed ID: 11733771 [TBL] [Abstract][Full Text] [Related]